Back to top

Image: Bigstock

Epizyme, Inc.

Read MoreHide Full Article

Epizyme’s efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. Moreover, the company’s efforts on evaluating tazemetostat, in combination with anti-PD 1 or PDL-1 agent, are also encouraging. The company’s collaboration agreement with Celgene for small-molecule HMT inhibitors including pinometostat is a big positive. However, with no approved product in its kitty, Epizyme is highly dependent on its collaboration partners for top-line growth. Moreover, most of its candidates are in early stages of development and hence several years away from commercialization. Epizyme’s share price has outperformed the Zacks classified Medical/Biomedical Genetics industry in the last twelve months. The stock gained 14.8% during this time period compared to the industry’s 11.3% drop.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Epizyme, Inc. (EPZM) - free report >>

Published in